Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

Linaprazan didn’t make much of a mark at AstraZeneca. Despite showing promise in early-stage studies, the potassium competitive acid blocker, or PCA-B, failed to beat Nexium, the pharma giant’s blockbuster proton pump inhibitor in treating acid reflux. The drug was then unceremoniously purged from the pipeline.